Ornithine-Transcarbamylase Deficiency Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Ornithine transcarbamylase (OTC Deficiency) deficiency is a rare X-linked genetic disorder characterized by complete or partial lack of the enzyme ornithine transcarbamylase (OTC Deficiency). OTC Deficiency plays an important role in the break down and removal of nitrogen in the body (urea cycle). The lack of the OTC Deficiency enzyme results in excessive accumulation of nitrogen, in the form of ammonia (hyperammonemia), in the blood. Symptoms include vomiting, refusal to eat, progressive lethargy, and coma.
The Ornithine-Transcarbamylase (OTC Deficiency) Deficiency Pipeline market research report provides comprehensive information on the therapeutics under development for Ornithine-Transcarbamylase Deficiency (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report also provides an overview of key players involved in therapeutic development for Ornithine-Transcarbamylase Deficiency and features dormant and discontinued projects.
OTC Deficiency Pipeline Products Market Segmentation by Target
The key target in the OTC Deficiency pipeline products market is Ornithine Carbamoyltransferase Mitochondrial.
OTC Deficiency Pipeline Products Market Segmentation by Mechanism of Action
The key mechanism of action in the OTC Deficiency pipeline products market is Ornithine Carbamoyltransferase Mitochondrial Activator.
OTC Deficiency Pipeline Products Market Segmentation by Routes of Administration
The key routes of administration in the OTC Deficiency pipeline products market are intravenous, and intrahepatic. Most of the pipeline products are administered through the intravenous route.
OTC Deficiency Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights into the OTC Deficiency pipeline products market, download a free report sample
OTC Deficiency Pipeline Products Market Segmentation by Molecule Types
The key molecule types in the OTC Deficiency pipeline products market are gene therapy, oligonucleotide, cell therapy, and small molecule. Gene therapy is the leading molecule type in the Ornithine-Transcarbamylase Deficiency pipeline products market.
OTC Deficiency Pipeline Products Market Analysis by Molecule Types
For more molecule type insights into the OTC Deficiency pipeline products market, download a free report sample
OTC Deficiency Pipeline Products Market - Competitive Landscape
Some of the leading companies in the OTC Deficiency pipeline products market are Arcturus Therapeutics Holdings Inc, BioNTech SE, Bloomsbury Genetic Therapies Ltd, CAMP4 Therapeutics Corp, Cellaion SA, Gene Therapy Research Institution Co Ltd, iECURE, Lucane Pharma SA, Moderna Inc, and Poseida Therapeutics Inc. Arcturus Therapeutics Holdings Inc is the leading company in the Ornithine-Transcarbamylase Deficiency pipeline products market.
OTC Deficiency Pipeline Products Market Analysis by Companies
To know more about the leading players in the OTC Deficiency pipeline products market, download a free report sample
OTC Deficiency pipeline Products Market Report Overview
| Key Target | Ornithine Carbamoyltransferase Mitochondrial |
| Key Mechanism of Action | Ornithine Carbamoyltransferase Mitochondrial Activator |
| Key Routes of Administration | Intravenous, and Intrahepatic |
| Key Molecule Type | Gene Therapy, Oligonucleotide, Cell Therapy, and Small Molecule |
| Leading Companies | Arcturus Therapeutics Holdings Inc, BioNTech SE, Bloomsbury Genetic Therapies Ltd, CAMP4 Therapeutics Corp, Cellaion SA, Gene Therapy Research Institution Co Ltd, iECURE, Lucane Pharma SA, Moderna Inc, and Poseida Therapeutics Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ornithine-Transcarbamylase Deficiency (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Ornithine-Transcarbamylase Deficiency (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ornithine-Transcarbamylase Deficiency (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ornithine-Transcarbamylase Deficiency (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ornithine-Transcarbamylase Deficiency (Genetic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ornithine-Transcarbamylase Deficiency (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ornithine-Transcarbamylase Deficiency (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
BioNTech SE
Bloomsbury Genetic Therapies Ltd
CAMP4 Therapeutics Corp
Cellaion SA
Gene Therapy Research Institution Co Ltd
iECURE
Lucane Pharma SA
Moderna Inc
Poseida Therapeutics Inc
Sana Biotechnology Inc
Ultragenyx Pharmaceutical Inc
Unicyte AG
Table of Contents
Table
Figures
Frequently asked questions
-
What is the key target in the OTC Deficiency pipeline products market?
The key target in the OTC Deficiency pipeline products market is Ornithine Carbamoyltransferase Mitochondrial.
-
What are the key mechanisms of action in the OTC Deficiency pipeline products market?
The key mechanism of action in the OTC Deficiency pipeline products market is Ornithine Carbamoyltransferase Mitochondrial Activator.
-
What are the key routes of administration in the OTC Deficiency pipeline products market?
The key routes of administration in the OTC Deficiency pipeline products market are intravenous, and intrahepatic.
-
What are the key molecule types in the OTC Deficiency pipeline products market?
The key molecule types in the OTC Deficiency pipeline products market are gene therapy, oligonucleotide, cell therapy, and small molecule.
-
Which are the leading companies in the OTC Deficiency pipeline products market?
Some of the leading companies in the OTC Deficiency pipeline products market are Arcturus Therapeutics Holdings Inc, BioNTech SE, Bloomsbury Genetic Therapies Ltd, CAMP4 Therapeutics Corp, Cellaion SA, Gene Therapy Research Institution Co Ltd, iECURE, Lucane Pharma SA, Moderna Inc, and Poseida Therapeutics Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Other Diseases reports